Tern Plc Wyld Networks warrant exercise

TERN

Tern Plc (LON:TERN), the company focused on value creation from Internet of Things technology businesses, has announced that it has committed to exercise the 320,454 TO1 Warrants in Wyld Networks AB which represents all of the TO1 Warrants that were issued to Tern pursuant to its investment as part of Wyld Networks’ Offering in conjunction with Wyld Networks’ IPO and admission to trading on the NASDAQ First North Growth Market in Stockholm on 2 July 2021.

Tern will pay SEK 3,605,108 (approximately £290,000) to exercise its TO1 Warrants to subscribe for 320,454 shares in Wyld Networks at SEK 11.25 per share, and this will be funded from Tern’s existing cash resources.

Prior to the completion of the TO1 Warrant exercises Tern held 58.7% of Wyld Networks’ issued share capital.  The subscription period for the in aggregate, 2,275,000 TO1 Warrants commenced on 22 March 2022 and will end on 4 April 2022.  If all of the TO1 Warrants are exercised Tern’s holding in Wyld Networks will reduce to 49.1% and a further announcement regarding Tern’s resultant holding in Wyld Networks will be made when the exercise period for the TO1 Warrants is completed.

Wyld Networks is a virtual satellite network operator that develops and delivers innovative wireless technology solutions that enable affordable connectivity for IoT devices and sensors anywhere in the world – especially for the 85% of the world’s surface where there are no cellular networks.  For the year ended 31 December 2020, Wyld Networks’ audited loss for the year was SEK 9,536,000 (2019: loss of SEK 6,602,000) on net sales of SEK 2,475,000 (2019: SEK 1,559,000) and its audited total assets as at 31 March 2020 were SEK 5,752,000 (31 December 2019: SEK 5,636,000).

Capitalised terms not otherwise defined herein have the same meaning as in the Tern plc announcement “Proposed IPO of Wyld Networks” made on 9 June 2021.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Evidence-based care pathways support more consistent healthcare delivery

Evidence-based care pathways can improve diagnosis, treatment consistency and the integration of new therapies into routine care.

Tern increases Talking Medicines funding and raises shareholder distribution commitment

Tern has invested in additional Talking Medicines convertible loan notes and increased its minimum shareholder distribution commitment to 70% on qualifying exits.

Evidence-based care pathways create clearer routes to adoption

Evidence-based care pathways can reduce delays, improve treatment consistency and support the adoption of new therapies.

Talking Medicines highlights the data opportunity emerging around GLP-1 care

Talking Medicines examines how the expanding GLP-1 market is increasing the importance of clear distinctions between approved therapies, compounded medicines and nutritional support.

Tern plc raises £450,000 in share placing ahead of AIM admission

Tern plc has raised £450,000 through a placing and outlined expected admission timing and updated voting rights.

AI search makes message measurement a healthcare priority

As AI changes search, healthcare companies need to know whether their messages are being seen, understood and represented correctly.

Search